ASCO 2022 | Two-year follow-up of ZUMA-3: safety and efficacy of brexu-cel in patients with R/R B-ALL
Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of two-year follow up results from the Phase III ZUMA-3 trial (NCT02614066) evaluating brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 CAR-T cell therapy approved in the US, to treat adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this interview, Dr Shah discusses outcomes with longer follow-up in these patients and in a larger pooled analysis of Phase I and II patients who received the pivotal dose of brexu-cel. Dr Shah also comments on the impact of tumor burden and age on toxicity, and further discusses the future of CAR-T therapy for the treatment of B-ALL. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
